Gene Therapy Market Outlook 2024-2035: Competitive Insights, Revenue Projections & Segment Expansion

The gene therapy market is expected to grow from USD 4.20 billion in 2025 to USD 6.07 billion in 2026 and USD 20.47 billion by 2035, at a CAGR of 14.5%.

It is worth highlighting that, more than 390 gene therapies have either received regulatory approval or are currently being evaluated in across various phases of clinical trials to assess the safety and effectiveness of these medications in patients diagnosed with different types of inherited disorders. In fact, close to 5% of the gene therapies have already been marketed, of which 30% of the therapies are intended for the treatment of various hematological disorders that are caused due to abnormalities in specific genes of an individual.

Additionally, at present, 920 gene therapies are either in discovery stage or being evaluated in preclinical studies, of which 60% of the therapies are being developed to be delivered using adeno-associated virus vectors. Further, during our research, we identified 345 gene therapy developers / gene therapy companies that are engaged in the development of gene therapies. The majority (58%) of gene therapy developers were established during the period 2011-2020. This period has seen a notable increase in the number of players entering the gene therapy domain, reflecting a stable and enticing industry for the new entrants.

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/gene-therapies-market/268.html